March 7, 2019
- Estudio de seguridad revela el riesgo de coágulos de sangre en los pulmones y muerte con una dosis más alta de tofacitinib (Xeljanz, Xeljanz XR) en pacientes con artritis reumatoide; la FDA investigará
- FDA Drug Shortages
- Buspirone HCl Tablets (Updated - Currently in Shortage)
- Carbidopa and Levodopa Extended Release Tablets (Updated - Currently in Shortage)
- Cefazolin Injection (Updated - Currently in Shortage)
- Cefepime Injection (Updated - Currently in Shortage)
- Dexamethasone Sodium Phosphate Injection (Updated - Currently in Shortage)
- Diltiazem Hydrochloride ER (Twice-a-Day) Capsules (Updated - Currently in Shortage)
- Ketamine Injection (Updated - Currently in Shortage)
- Ketorolac Tromethamine Injection (Updated - Currently in Shortage)
- Leucovorin Calcium Lyophilized Powder for Injection (Updated - Currently in Shortage)
- Penicillamine (Depen) Titratable Tablets (Updated - Currently in Shortage)
- Piperacillin and Tazobactam (Zosyn) Injection (Updated - Currently in Shortage)
- Thiothixene Capsules (Updated - Currently in Shortage)
- Trifluoperazine Hydrochloride Tablets (Updated - Currently in Shortage)
- Nonproprietary Naming of Biological Products: Update Guidance for Industry (PDF - 322KB)
- Manual of Policies and Procedures (MAPP) 6720.5 Procedures for Handling Requests for Nonproprietary Name Suffix Review for Biological Products Newly Licensed Under Section 351of the PHS Act (PDF - 80KB)
.png)
No hay comentarios:
Publicar un comentario